Jazz Pharmaceuticals
Presença
Jazz Pharmaceuticals é uma das ...
Jazz Pharmaceuticals é uma empresa listada sob o símbolo JAZZ (IE).
Jazz Pharmaceuticals tem presença direta em 3 países.
Executivos
Veja o organograma con seus 35 executivos principais
Biografias mais buscadas da Jazz Pharmaceuticals
- Bruce Cozadd, Chairman and Chief Executive Officer
- Seamus Mulligan, Director
- Kenneth O'Keefe, Director
Recentes movimentos de executivos em Jazz Pharmaceuticals
- Patrick Kennedy, ingressou na Companhia como Director (Notícia publicada em 28 de fevereiro de 2024).
- Philip Johnson ingressará na Companhia como Executive Vice President and Chief Financial Officer em 15 de mar. de 2024 (Notícia publicada em 22 de fevereiro de 2024).
- Daniel Swisher, President and Chief Operating Officer, irá se aposentar em 1 de out. de 2023 (Notícia publicada em 13 de setembro de 2023).
Clique aqui para ver outras movimentos em Jazz Pharmaceuticals
Criar um alerta
para seguir os movimentos de executivos da Jazz Pharmaceuticals.
Farmacêutica
Jazz Pharmaceuticals possui 1.860 concorrentes concorrentes Pfizer (Estados Unidos), Johnson & Johnson (Estados Unidos) e Sanofi (França).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Jazz Pharmaceuticals
- Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022 | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals and Redx Announce Pan-RAF Inhibitor JZP815 to Enter Clinical Development | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist | Jazz Pharmaceuticals plc
- View more press releases Close
Redes sociais sobre Jazz Pharmaceuticals
- Jazz Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Jazz Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Bruce Cozadd 
Ligue para a Jazz Pharmaceuticals em +1 650...
